Centre for Probe Development and Commercialization Products Recall (2019-04-17)
· Published by Health Canada · Official notice
Alert type: Drug Recall
Category: Drugs
Issue: Product Safety
Audience: General Public, Healthcare Professionals, Hospitals
Department: Health Canada
Hazard classification: Type III
A. Glucovision (Phosphate) 540 GBQ / Vial solution
| Lot or serial number | Companies | Brand name | Dosage form | DIN, NPN, DIN-HIM | Strength |
|---|
| T-190417FDG-1 | - Recalling Firm
- Centre for Probe Development and Commercialization (CPDC)
- 1280 Main St. W. NRB-A316
- Hamilton
- L8S 4K1
- Ontario
- CANADA
- Marketing Authorization Holder
- Centre for Probe Development and Commercialization (CPDC)
- 1280 Main St. W. NRB-A316
- Hamilton
- L8S 4K1
- Ontario
- CANADA
| B. Glucovision (Citrate) 453 GBQ / Vial solution | Solution | DIN 02328771 | Fludeoxyglucose 18F 453 GBQ/vial |
| T-190417FDG-2 | - Recalling Firm
- Centre for Probe Development and Commercialization (CPDC)
- 1280 Main St. W. NRB-A316
- Hamilton
- L8S 4K1
- Ontario
- CANADA
- Marketing Authorization Holder
- Centre for Probe Development and Commercialization (CPDC)
- 1280 Main St. W. NRB-A316
- Hamilton
- L8S 4K1
- Ontario
- CANADA
| A. Glucovision (Phosphate) 540 GBQ / Vial solution | Solution | DIN 02486652 | Fludeoxyglucose 18F 540 GBQ/vial |
A. Glucovision (Phosphate) 540 GBQ / Vial solution
B. Glucovision (Citrate) 453 GBQ / Vial solution
Affected lots may contain particulate matter.
Healthcare establishments, End users